Leading Health and Life Sciences in Nova Scotia

IMV featured on CTV: NS lab gets green light to test COVID-19 vaccine on humans

Watch here

A Nova Scotia laboratory working on a vaccine for COVID-19 has been given the green light from Health Canada to proceed with its plan for human trials.

“The clinical team is putting together the final documents for Health Canada final approval, to move that into the clinic,” says Marianne Stanford, the vice-president of research and development of IMV Inc. “We’re putting all the pieces together to get this done.”

IMV is a biopharmaceutical company with labs in Dartmouth, N.S. The company started working on a vaccine for the novel coronavirus as soon as the World Health Organization declared the pandemic.

Health Canada has now approved IMV’s design for its Phase 1 clinical study, which will test the vaccine in 84 healthy adults.

Phase 1 will test the safety of the vaccine itself. The study is unique in that it will test the vaccine on two age groups — adults between 18 and 55 years old and adults 56 years of age and older. Two doses of the vaccine will be tested on both groups.

“We’re one of the first to focus in that [older] age group for initial clinical trial,” says Stanford, “and I think that’s really based on the fact that we have previous data with that age group.”


IMV Inc. provides clinical and operational update and announces first quarter 2020 financial results

Read original here

IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced financial results for the first quarter ended March 31, 2020 and provided an update on its clinical and operational progress.

“Despite the current pandemic, we have continued to validate our platform and advance our clinical pipeline targeting various cancers and other serious diseases, including COVID-19,” said Frederic Ors, Chief Executive Officer at IMV. “Today, we are especially pleased to announce that SPiReL, a Phase 2 study of a DPX-Survivac combination regimen in patients with r/r DLBCL, has met its primary efficacy endpoint. This represents a significant milestone for DPX-Survivac, which has so far demonstrated the ability to shrink both solid and hematological tumors with long-lasting clinical responses and a differentiated safety profile. We believe these results in r/r DLBCL, taken together with emerging data from our DeCidE1 study in advanced ovarian cancer, support our plan to accelerate development in both of these indications.”

Mr. Ors continued, “Our recent financing fortifies our corporate position, with cash to fund operations for more than 12 months and several milestones anticipated across our portfolio in the interim. We look forward to presenting translational and updated clinical response data from DeCidE1 at the ASCO20 Virtual Scientific Program, and to further updates from each of our Phase 2 studies of DPX-Survivac later this year. Additionally, we are preparing to advance a DPX-based vaccine candidate for COVID-19, which is on track to enter into clinical trials later this summer.”

IMV Inc. Announces Closing of $25.1 Million Private Placement

Read original here

IMV Inc. a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including COVID-19, today announced that it has completed its previously announced non-brokered private placement (the “Private Placement”) of 8,770,005 units of the Company (each, a “Unit”) at Cdn$2.86 per Unit for gross proceeds of approximately Cdn$25.1 million. The size of the Private Placement has increased by approximately Cdn$2.8 million following our earlier announcement on April 30, 2020.

The Company intends to use the net proceeds from the Private Placement for the clinical development of its lead candidate, DPX-Survivac, currently being assessed in advanced ovarian cancer, as well as in multiple clinical studies in combination with Merck’s Keytruda®. The balance of the net proceeds will be used for general corporate purposes, including funding research and development, preclinical and clinical expenses, and corporate costs.

NSBI : A spotlight on how some Nova Scotian companies are pivoting operations to help the fight against COVID-19

Read original here

From producing protective equipment and hand sanitizer, to innovating medical technology, here’s how some Nova Scotia companies are changing the way they do business.

In response to COVID-19, IMV initiated the development of a vaccine. The company is currently in the preclinical development stage.

As innovation companies and health partners step up to collaborate on new products with Spring Loaded, current projects include the development of a face shield and transport hood.